| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– KOMZIFTI®(ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – |
| 09 Sep 2026 |
8-K: Other Events
Kura Oncology, Inc. (the “Company”) formed a wholly owned subsidiary, Caspian Therapeutics, Inc. (“Caspian”), to focus on the development of next-generation menin inhibitors for the treatment of diabetes and other cardiometabolic disease... |
| 08 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
– KOMZIFTI®(ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – |
| 29 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 24, 2026, Kura Oncology, Inc. (the “Company”) entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer (the “Wilson ... |
| 04 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – |
| 29 Jan 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporati... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved |
| 02 Dec 2025 |
8-K: Other Events
On December 2, 2025, Kura Oncology, Inc. (the “Company”) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under the Company’s collaboration and license agreement with Kyowa Kirin Co., Ltd. and Kyowa ... |
| 13 Nov 2025 |
8-K: Other Events
On November 13, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced that the U.S. Food and Drug Administration (“FDA”) has granted full approval of KOMZIFTITM (ziftomenib) for adult patients with... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
– KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – |
| 24 Oct 2025 |
8-K: Other Events
On October 24, 2025, Kura Oncology, Inc. (the “Company”) announced receipt of a $30 million milestone payment under its Collaboration and License Agreement with Kyowa Kirin, Inc. and Kyowa Kirin Co., Ltd. (together,“Kyowa Kirin”) in conn... |
| 16 Oct 2025 |
8-K: Other Events
(a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, a... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – |
| 01 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
On June 27, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin, Inc. (“Kyowa Kirin US”) entered into a Co-Promotion and Medical Affairs Agreement (the “Co-Promotion Agreement”) to co-promote the Company’s product candidate, ziftom... |
| 18 Jun 2025 |
8-K: Other Events
June 18, 2025 2025 EHA ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99.1 |
| 06 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. |
| 03 Jun 2025 |
8-K: Other Events
June 2, 2025 2025 ASCO ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer Exhibit 99.1 |
Loading...